申请人:YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.
公开号:EP0703222A1
公开(公告)日:1996-03-27
A 3-aminoazepine compound represented by general formula (I), an optically active isomer thereof, or a pharmaceutically acceptable salt thereof, wherein Ar represents phenyl, etc.; R¹ represents hydrogen, alkyl, etc.; R² and R³ represent each independently hydrogen, alkyl, -CO-R⁶ (wherein R⁶ represents heteroaryl, etc.), -CONH-R⁷ (wherein R⁷ represents phenyl, etc.), etc.; R⁴ represents hydrogen, alkyl, etc.; X represents oxygen or sulfur, provided R⁴ and X may be combined together to form -C(R¹⁰)=N-N= (wherein R¹⁰ represents hydrogen, alkyl, etc.). This compound has CCK and gastrin antagonisms and is useful as a remedy for central nervous system diseases such as anxiety and depression and as a preventive or a remedy for pancreatic diseases and gastrointestinal ulcer.
通式(I)代表的 3-氨基氮杂卓化合物、其光学活性异构体或其药学上可接受的盐,其中 Ar 代表苯基等;R¹ 代表氢、烷基等;R² 和 R³ 各自独立地代表氢、烷基、-CO-R⁶(其中 R⁶ 代表杂芳基等)、-CONH-R⁷(其中 R⁷ 代表苯基等)等;R⁴ 代表氢、烷基等。)、-CONH-R⁷(其中 R⁷ 代表苯基等)等;R⁴ 代表氢、烷基等;X 代表氧或硫,条件是 R⁴ 和 X 可以结合在一起形成 -C(R¹⁰)=N-N=(其中 R¹⁰ 代表氢、烷基等)。该化合物具有 CCK 和胃泌素拮抗作用,可用于治疗焦虑和抑郁等中枢神经系统疾病,以及预防或治疗胰腺疾病和胃肠道溃疡。